-+ 0.00%
-+ 0.00%
-+ 0.00%

XOMA Royalty Amends Its Collaboration, Originally Established In 2006, With Takeda Through Strategic Royalty Share Transaction

Benzinga·12/30/2025 12:38:59
Listen to the news
  • Takeda's royalty and milestone payment obligations to XOMA Royalty related to mezagitamab will be reduced
  • XOMA Royalty will receive payments based on low to mid-single-digit royalties and milestones across a basket of nine development-stage assets that are held within Takeda's externalized assets portfolio.
  • Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079)
  • XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine development-stage assets held within Takeda's externalized assets portfolio